Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is by far the most prevalent form of dementia in adults over 65 years old. Amyloid β peptide (Aβ)-containing senile plaques are one of the neuropathological hallmarks of AD. The gradual accumulation of aggregated Aβ peptide initiates a complex multistep cascade, which include gliosis, inflammatory changes, oxidative stress, tangle formation (microtubule changes), neuritic/synaptic changes, and transmitter loss that finally lead to dementia. One of the strategies used to increase the clearance of Aβ peptide from the brain involves immunization with Aβ peptide 1–42 (Aβ1–42). However, clinical trials of active immunization were halted when patients in the study developed meningocephalitis. We have recently reported that semi-allogeneic somatic cell hybrids generated by the fusion of EL-4 T lymphoma cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d) can protect C57BL/6 mice (H-2b) challenged with a tumorigenic dose of EL-4 cells. The results of our studies are entirely consistent with the concept that the semi-allogeneic vaccine (made of RAG X EL-4 cell hybrids) induce a potent T cell-mediated (Th-1) response, that instructs T lymphocytes to kill autologous (EL-4) tumor cells. We have subsequently modified RAG X EL-4 cell hybrids to specifically target Aβ1–42. Ten-week-old female C57BL/6 APP transgenic mice (APPswe, PSEN1dE9) were treated with a single dose of modified RAG X EL-4 somatic cell hybrids, injected intraperitoneally (i.p.). At six months of age, all mice were sacrificed and their brains were fixed and sectioned to count the amyloid plaques. We observed that the brains of APP mice, treated with a single dose of the semi-allogeneic cell hybrids formulated with Aβ1–42, showed less numerous and smaller plaques compared to the brains of APP mice treated with Aβ1–42 in PBS or with unmodified RAG X EL-4 cell hybrids in PBS. The results of these preliminary animal studies led us to hypothesize that a T cell-mediated (Th-1) immune response targeting the Aβ1–42 will help clear this peptide from the brain, resulting in enhanced cognition, without the risk of adverse events such as meningocephalitis.

AAV2/1 CD74 Gene Transfer Reduces Β-Amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease

Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.

Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Transfer of three transcription factors via a lentiviral vector ameliorates spatial learning and memory impairment in a mouse model of Alzheimer's disease.

A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice

AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice

A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis.

Active Beta-Amyloid Immunization Restores Spatial Learning in Pdapp Mice Displaying Very Low Levels of Beta-Amyloid

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease

FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders

P2‐359: Cathepsin B Gene Deletion or Inhibition Improves Memory Deficits in a Mouse Model of Alzheimer's Disease Expressing APP with the Wild‐type Beta‐secretase Site

A Tetravalent TREM2 Agonistic Antibody Reduced Amyloid Pathology in a Mouse Model of Alzheimer's Disease.

RESEARCH ON THE NEUROPROTECTIVE EFFECT OF AD WITH THE RECOMBINANT ADENO-ASSOCIATED VIRUS SYSTEM FUSING WITH ABAD-DP

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice

Ganoderic Acid A Promotes Amyloid-β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer’s Disease (Mouse Model) Through Autophagy Induced by Activating Axl

Cart Treatment Improves Memory and Synaptic Structure in App/Ps1 Mice

Gene therapy using Aβ variants for amyloid reduction

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

AVP(4-8) Improves Cognitive Behaviors and Hippocampal Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer’s Disease